{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:54:22Z","timestamp":1788285262169,"version":"build-2803163510"},"reference-count":18,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"DOI":"10.1182\/hematology.2022000412","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T11:12:43Z","timestamp":1670584363000},"page":"491-494","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?"],"prefix":"10.1182","volume":"2022","author":[{"given":"George","family":"Goshua","sequence":"first","affiliation":[{"name":"1 Section of Hematology, Yale University School of Medicine, New Haven, CT"},{"name":"2 Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan K.","family":"Bendapudi","sequence":"additional","affiliation":[{"name":"3 Division of Hematology and Blood Transfusion Service, Massachusetts General Hospital, Boston, MA"},{"name":"4 Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, MA"},{"name":"5 Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"4","key":"2022121313282324500_hem2022000412C1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2022121313282324500_hem2022000412C2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"2022121313282324500_hem2022000412C3","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2022121313282324500_hem2022000412C4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2022121313282324500_hem2022000412C5","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"2022121313282324500_hem2022000412C6","article-title":"Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura [published online 5 August 2022]","author":"Pascual Izquierdo","journal-title":"Blood Adv"},{"issue":"2","key":"2022121313282324500_hem2022000412C7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2022121313282324500_hem2022000412C8","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(20)30406-3","article-title":"NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpura","volume":"8","author":"Hughes","year":"2021","journal-title":"Lancet Haematol"},{"key":"2022121313282324500_hem2022000412C9","unstructured":"National Institute for Health and Care Excellence. Final appraisal document: caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura. https:\/\/www.nice.org.uk\/guidance\/ta667\/documents\/final-appraisal-determination-document. Accessed 18October2022."},{"issue":"5","key":"2022121313282324500_hem2022000412C10","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3026(21)00052-1","article-title":"Accurate accounting of caplacizumab cost effectiveness","volume":"8","author":"Goshua","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"2022121313282324500_hem2022000412C11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/trf.15721","article-title":"Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura","volume":"60","author":"Colling","year":"2020","journal-title":"Transfusion"},{"issue":"12","key":"2022121313282324500_hem2022000412C12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood.2022016640","article-title":"Race, rituximab, and relapse in TTP","volume":"140","author":"Chaturvedi","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2022121313282324500_hem2022000412C13","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"2022121313282324500_hem2022000412C14","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"key":"2022121313282324500_hem2022000412C15","article-title":"Management of thrombotic thrombocytopenic purpura (TTP) without plasma exchange: an update on the Austrian experience","author":"Kn\u00f6bl"},{"issue":"7","key":"2022121313282324500_hem2022000412C16","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2022121313282324500_hem2022000412C17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjh.13658","article-title":"Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative","volume":"171","author":"Bendapudi","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"2022121313282324500_hem2022000412C18","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/bloodadvances.2019031039","article-title":"Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura","volume":"3","author":"Sun","year":"2019","journal-title":"Blood Adv"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/491\/2023185\/491goshua.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/491\/2023185\/491goshua.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T08:29:30Z","timestamp":1670920170000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/491\/493545\/Evidence-Based-Minireview-Should-caplacizumab-be"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000412","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}